Melanotan
Bare “Melanotan” is an unresolved umbrella — MT1 ≠ MT2 ≠ bremelanotide; no single CID/CAS badge.
Editorial review:Evidence snapshot
This drawer marks papers. It is not a plan, a dose, or a source. A paper is a bounded report. It is not a protocol. Grades name the object. They are not a safety rating.
Identity lock — AMBIGUITY IS THE POINT. The bare word “Melanotan” does not uniquely name one molecule in the wild:
| Label people say | Actual chemistry / product | Where graded on this site |
|---|---|---|
| Melanotan 1 / MT-I / afamelanotide | Linear [Nle⁴, D-Phe⁷]-α-MSH; Scenesse implant is the labeled EPP object | Separate drawer: melanotan-1.md |
| Melanotan II / MT-II | Cyclic lactam α-MSH analogue; not FDA-approved for tanning or sexual dysfunction | Separate WAVE1 drawer: melanotan-ii.md |
| Bremelanotide / PT-141 / Vyleesi | Related melanocortin agonist; FDA-approved for premenopausal HSDD (labeled object) | Separate drawer: bremelanotide / PT-141 |
| Bare “Melanotan” (this drawer) | Unresolved street/marketing umbrella — PubChem synonym “Melanotan” often redirects to afamelanotide (MT-I), while population/case-report language frequently means MT-II or unspecified α-MSH analogues | Ambiguity drawer only — do not invent a single CID/CAS badge |
PubChem synonym trap: name lookup “Melanotan” often resolves to afamelanotide CID 16197727 — that is the MT-I synonym collision, not a badge for this bare-label drawer. Do not invent a merged molecule. Point readers to the identity-resolved drawers. This drawer marks ambiguity, population-risk, and detection literature that uses the bare or mixed label. It is not use advice.
Bottom line
“Melanotan” in general-population, case-report, and underground-market papers is often an unresolved or mixed α-MSH-analogue label. Discovery narratives explicitly treat Melanotan-I and Melanotan-II as two drugs. Regulated afamelanotide (Scenesse) for EPP is not the same as gray-market tanning vials under any melanotan name. Honest Status copy must force disambiguation before any efficacy grade.
Papers
Explicit I vs II separation / discovery
PMID 9760697 — Hadley 1998
Tested: discovery/development narrative for Melanotan-I and Melanotan-II as distinct melanogenic drug candidates.
Does not show: that bare “Melanotan” is one approved product.
PMID 19224885 — Evans-Brown 2009
Tested: commentary on use of melanotan I and II in the general population (mixed-label public-health framing).
Does not show: efficacy or safety establishing medical cosmetic use for either, or a single-molecule identity.
PMID 28266027 — Habbema 2017
Tested: review of risks of unregulated α-MSH analogue use (melanotan I/II), contrasting with separately regulated afamelanotide context.
Does not show: that unregulated products are safe or identical to Scenesse.
Bare / mixed “Melanotan” population & market context
PMID 22051769 — Mahiques-Santos 2012
Tested: dermatologic clinical commentary titled/framed around “Melanotan” as used in practice literature (Spanish-language clinical note context).
Does not show: a locked CID for the bare label; treat as mixed-label clinical warning context.
PMID 30142729 — Callaghan 2018
Tested: glimpse into the underground market of melanotan (market/observational framing).
Does not show: pharmaceutical identity or approved indication.
PMID 24771717 — Breindahl 2015
Tested: LC-UV-MS/MS identification of melanotan II in illegal internet skin-tanning products — shows how “melanotan” market listings often resolve analytically to MT-II.
Does not show: that every bare “Melanotan” listing is MT-II; demonstrates the ambiguity problem.
Case-report / harm-signal context under melanotan labels
PMID 30796078 — Dreyer 2019
Tested: case report of melanotan-associated priapism (label as reported in the case — not a clean identity lock for MT-I vs MT-II without product confirmation).
Does not show: controlled efficacy; identity may be unresolved at point of care.
PMID 31953620 — Peters 2020
Tested: case/review framing Melanotan II and possible renal infarction — MT-II-named harm signal.
Does not show: bare-label identity resolution for all “melanotan” exposures.
PMID 21564053 — Paurobally 2011
Tested: melanotan-associated melanoma case framing (association/signal — causality not proven by case reports alone).
Does not show: definitive causal melanoma proof or a single-molecule badge.
What is not established
A single chemical identity for bare “Melanotan.” Equivalence of gray-market melanotan products to afamelanotide (Scenesse), to Melanotan II research material, or to FDA-approved bremelanotide. Safe cosmetic tanning from unregulated α-MSH analogues. This drawer does not provide use advice, schedules, or sourcing. Use melanotan-1.md or melanotan-ii.md once identity is known.
Selected sources
9760697 19224885 28266027 22051769 30142729 24771717 30796078 31953620 21564053
Reported experiences
Reported topics are not established benefits.Risks and unknowns
Compare experiences with care.
Join the discussion
Verified members can contribute to compound conversations.